← Browse by Condition
Medical Condition

pancreatic neuroendocrine tumor

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for pancreatic neuroendocrine tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pancreatic neuroendocrine tumor Clinical Trials

How many clinical trials are currently recruiting for pancreatic neuroendocrine tumor?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for pancreatic neuroendocrine tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic neuroendocrine tumor?
pancreatic neuroendocrine tumor research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic neuroendocrine tumor clinical trial?
Eligibility criteria for pancreatic neuroendocrine tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Changhai Hospital 1 trial
Merck Sharp & Dohme LLC 1 trial
Anusha Kalbasi 1 trial

Recruiting Clinical Trials

NCT07439757
Recruiting
AI-Powered Precision Decision-Making for Pancreatic Diseases
Enrollment
2,000 pts
Location
China
Sponsor
Changhai Hospital
View Trial →
NCT04924075 Phase 2
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Enrollment
355 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
View Trial →
NCT04119024 Phase 1
Recruiting
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Enrollment
18 pts
Location
United States
Sponsor
Anusha Kalbasi
View Trial →

Related Conditions

pancreatic cancer (1) diagnose disease (1) ipmn pancreatic (1) pancreatic cystic lesions (1) chronic pancreatitis (1) acute pancreatitis ap (1) pheochromocytoma paraganglioma (1) von hippel lindau disease (1) advanced gastrointestinal stromal tumor (1) hif 2 mutated cancers (1) metastatic malignant solid neoplasm (1) metastatic melanoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology